EIR-1003 / EIR Biopharma - LARVOL DELTA

EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug. (FierceBiotech) - "The biotech has earmarked $2 million of the proceeds to take EIR-1003, its lead drug for eye conditions like glaucoma, diabetic retinopathy and uveal melanoma, through preclinical development. Another $5 million will be set aside to bankroll phase 1/1b clinical trials, which are penciled in for 2027, EIR explained in the filing."

Financing • New P1 trial • Diabetic Retinopathy • Glaucoma • Uveal Melanoma